Introduction
There have been three global influenza pandemics in the 20th century: the "Spanish flu" caused by 1918 H1N1, the "Asian flu" caused by 1957 H2N2, and the "Hong Kong flu" caused by 1968 H3N2. In 1977, the H1N1 subtype reappeared together with the H3N2 influenza virus; both strains were relatively prevalent and, until now, had regularly resurfaced as seasonal epidemics (Palese, 2004; Neumann et al., 2009) .
In March 2009, a novel influenza A H1N1 virus appeared and spread rapidly to many countries and regions worldwide, developing into a global influenza pandemic (http://www. who.int). Studies showed that the 2009 H1N1 was a novel swine-origin recombinant virus, of which 6 genes (PB2, PB1, PA, HA, NP, and NS) were similar to triple-reassortant swine influenza viruses circulating in pigs in North America, while two genes (NA and M) were similar to the versions seen in influenza strains common to Eurasian swine (Novel SwineOrigin Influenza A (H1N1) Virus Investigation Team, 2009; Smith et al., 2009; Trifonov et al., 2009) .
To date, this novel cross-species transmitted virus -2009 H1N1 -has been epidemic in the population for more than a year. Following steps will play an important role in the prediction of its epidemic trend and in vaccine development: 1) analysis of the similarity of antigenic and genetic characteristics among the 2009 H1N1 strains, representative seasonal H1N1 strains from different periods, and vaccine strains; 2) monitoring of its antigenic and molecular pathogenic characteristics in the epidemic process; and 3) improving the understanding of its genetic and variation rules. We therefore isolated, identified and analyzed the genome sequence of the 2009 H1N1 pandemic strains in Guangdong, China. We also analyzed the epitope, genetic and evolutionary characteristics of 2009 H1N1 isolated in China, in other countries and regions, seasonal H1N1 virus strains from different periods, and vaccine strains.
Materials and Methods
Isolation and identification of the virus. Nasopharyngeal swabs of influenza-suspected patients were taken and analyzed using a novel H1N1 real-time PCR kit (Daan, China). Since this study was part of the public health program implemented by the Ministry of Health of the People's Republic of China, there was no need of ethical approval. Positive samples were inoculated into MDCK cells and maintained in Opti-MEM minimum essential medium (Invitrogen, USA) containing 0.5 mg/ml trypsin. The cells were cultured at 35°C in the presence of 5% CO 2 . After significant cytopathic effect occurred, hemagglutination and hemagglutination inhibition identification tests were performed (Kendal et al., 1982) .
Nucleotide sequencing. The RNeasy mini kit (Qiagen, Germany) was used to extract viral RNA from cell culture supernatants. Reverse transcription of viral cDNA was performed using random primers (N6). Forty-five pairs of primers were designed to amplify the entire viral genome (Hoffmann et al., 2001; Wang and Lee, 2009; Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, 2009) . A gel extraction kit (Omega, USA) was used for the isolation of amplified PCR products. Sequencing was performed using an ABI sequencer (Applied Biosystems, USA).
Analyses of genetic and evolutionary characteristics. Protein sequences of 2009 H1N1 from different countries and regions obtained before August 2010 were downloaded from the influenza virus genome database; protein sequences of representative seasonal H1N1 strains from different periods, vaccine strains and swine influenza viruses were also downloaded. Clustal X and Mega 4.0 software were used to analyze variations in glycosylation sites, virulence-related sites, and antigenic sites of H1N1 viruses. 3D-JIGSAW was used for online prediction of 3D structures of viral HA and NA proteins.
Epitope prediction and analysis of conservation. The sequences of H1N1 viruses were input into the Immune Epitope Database (IEDB) and the artificial neural network (ANN) method was used for online prediction of HLA Class I epitope (CTL epitope). The unit of CTL epitope prediction measurement was IC50 (nM); lower IC50 values represented higher affinity. Typically, IC50 values of less than 50 nM represented high binding capacity, 50-500 nM represented moderate binding capacity, and higher than 500 nM represented low binding capacity (http://tools.immuneepitope.org).
CTL epitopes that were both nine amino acids long and had IC50 values of less than 500 were selected. The epitope conservancy analysis tool was used to analyze cross-conserved CTL epitopes among the 2009 H1N1 viruses, representative seasonal H1N1 strains and vaccine strains. Some T-cell epitopes show allele promiscuity; epitopes with up to two altered amino acids out of any 9-mer frame can still bind with the allele groove of HLA and the original T-cell receptor (Lichterfeld et al., 2006) . When evaluating the epitope conservation, we set the sequence similarity to ≥7/9 (77.8%).
Results

Virus isolation and sequencing
135 strains of 2009 H1N1 were isolated during the epidemic period. These isolates were named according to the isolation dates. We selected the representative epidemic strains from the different periods and sequenced the fulllength genome of 2009 H1N1. The sequences have been submitted to GenBank, with accession numbers of GQ244322-GQ244325, GQ223434-GQ223447, HM780470-HM780492, and HQ011407-HQ011424.
Analysis of glycosylation sites
The HA protein of 2009 H1N1 virus had seven glycosylation sites at positions 28, 40, 104, 293, 304, 498, and 557 . These glycosylation sites were located on the lateral side of HA molecule, with no glycosylation sites near the RBD. However, further analysis indicated that Haishu/SWL110/10 and Beijing/SE2649/09 from China, and Russia/178/09, Russia/180/09 and Salekhard/01/09 from other regions, isolated after November 2009, gained a novel glycosylation site at the position 179 near the RBD. Interestingly, the 1918 H1N1 virus also has no glycosylation sites near the RBD, but the seasonal H1N1 viruses gained in the epidemic process at least two glycosylation sites near the RBD of their HAs, such as at positions 144 and 179 in Marton/43, at positions 142, 172, and 177 in Denver/1/57, and at positions 142 and 177 in Guangzhou/506/06 (Fig. 1) .
The NA protein of 2009 H1N1 virus had seven glycosylation sites at positions 50, 58, 63, 68, 88, 146, and 235 . The strains isolated in China have no mutation at the glycosylation sites. However, Rome/623/09, Texas/45103737/09, and Texas/45071344/09 isolated in other regions after September 2009 had a new glycosylation site at the position 44. We also found that 1918 H1N1 has no glycosylation site at the position 44, but seasonal H1N1 viruses isolated after 1933 gained a glycosylation site at the position 44 in the epidemic process.
Analysis of antigenic sites
X-ray crystal diffraction and monoclonal antibody analysis showed that the head of the H1N1 HA protein contained five antigenic sites: Cb (residues 78-83), [156] [157] [158] [159] [160] [162] [163] [164] [165] [166] [167] , [206] [207] [208] [238] [239] [240] , and Ca2 (residues 140-145 and 224-225) (H3 numbering) (Brownlee and Fodor, 2001 ). Analysis of antigenic sites showed that some 2009 H1N1 isolates had mutations at antigenic sites of the HA protein. These variations were primarily random mutations, but at two sites a variation trend was identified: at the Ca1 site, a Ser206Thr mutation was found in most epidemic strains, and at the Ca2 site, a Asp to Glu/Gly mutation of residue 225 was identified. These variations were minor and mainly restricted to changes of a single amino acid at a single antigenic site. However, there were several strains, which exhibited two or more mutated sites, such as the amino acid variations at Cb, Sa and Ca1 sites in Beijing/ SE2649/09, and the amino acid variations at Cb, Ca1 and Ca2 sites in Zhejiang-Yiwu/11/09. Further, in several of these isolated strains, two amino acid mutations were found at the same antigenic site, such as the mutations of residues 78 and 81 at the Cb site in Zhejiang-Yiwu/11/09. The NA protein contains antigenic sites at residues 153, 197-199, 328-336, 339-347, 367-370, 400-403 , and 431-434 (N2 numbering) (Colman et al., 1983) . The variation of NA antigenic sites of 2009 H1N1 strains was lower than observed in the HA protein. From 95 strains isolated from China, only 5 isolated strains, such as Guangdong/2361/09, showed mutations of one amino acid residue (Table 1) .
A/Guangdong/06/09 (abbreviated as GD06), an early isolate from Guangdong, China, was used as a representative strain and compared with four seasonal H1N1 vaccine strains recommended by the WHO (BJ/262/95, NC/20/99, SI/3/06 and BS/59/07) in years 1999 to 2010. The results showed that the similarities between the antigenic sites of the HA proteins of GD06 and the four seasonal vaccine strains listed above were only 44.0%, 50.0%, 50.0%, and 50.0%, respectively. GD06 showed only 44-52% antigen similarity with representative seasonal H1N1 strains from 1940 and later. But it had a high degree of similarity of antigenic sites with Henry/36 (68.0%) and strains from before 1940, especially with antigenic sites of Brevil Mission/1/18 of the 1918 pandemic strain (80.0%). The similarity of NA antigenic sites between GD06, representative seasonal H1N1 strains, and vaccine strains resembled that observed for the HA protein (Table 2) .
Prediction of CTL epitopes and analysis of conservation
CTL epitopes of H1N1 were restricted by HLA class I alleles. In this study, we used six HLA class I supertype alleles (A0101, A0201, A0301, A2402, B0702, and B4403) that are California/07/09 2) The HA protein has five antigenic sites, including 50 amino acid residues. The NA protein has seven antigenic sites, including 34 amino acid residues. Numbers before "/" show the total number of identical amino acid residues between GD06 and H1N1 representative strains. estimated to cover 99% of the population (de Groot and Berzofsky, 2004) . The results showed that the number of CTL epitopes restricted by these six supertype alleles in HA, NA, and NP proteins of GD06 were 38, 23, and 30, respectively, of which the A0201 allele restricted the most. When compared to the 2009 H1N1 vaccine strain California/07/09, the GD06 epitopes showed 100% conservation.
Compared with seasonal H1N1 isolates from different periods, the conservation of GD06 NP CTL epitope was the highest (76.7-100%); the conservation of the HA CTL epitope was 60.5-84.2%; and the conservation of NA CTL epitope was comparatively low (47.8-82.6%). NP, HA, and NA CTL epitopes of GD06 shared the highest similarity with the New Jersey/08/76 of the classical swine H1N1 isolated from human, with similarities of 100%, 84.2%, and 82.6%, respectively. NP, HA, and NA CTL epitopes of GD06 were also highly similar to Brevil Mission/1/18, with similarities of 90.0%, 81.6%, and 78.3%, respectively (Table 3) .
When compared to the vaccine strains (BJ/262/95, NC/20/99, SI/3/06, and BS/59/07), the conservation of CTL epitopes of the HA protein in GD06 was 60.5-65.8%, including 23 commonly conserved epitopes. Additionally, GD06 had two conserved epitopes in the HA protein: YPKLSKSYI, which was not conserved in BJ/262/95 but was conserved in the other three strains analyzed; and FYKNLIWLV, which was only conserved in SI/3/06. The conservation of the NA CTL epitopes was 69.6-82.6%, including 16 commonly conserved epitopes. In addition, GD06 has three conserved epitopes in the NA protein: NSDTVGWSW and WPDGAELPF were not conservative in SI/3/06, but conservative in the other three strains analyzed; and AELPFTIDK, only conservative in BJ/262/95. Because the NP protein sequence of SI/3/06 and BS/59/07 was not available, we selected Taiwan/71720/07 from the same period for comparison. GD06 had 23 common epitopes with two vaccine strains and Taiwan/71720/07 with the conservation of 76.7% (Table 4) .
Discussion
T-cell epitopes (HLA class I and II epitopes) play an important role in the immunological response to the in- Numbers in bold represent the total of CTL epitopes restricted by the selected "supertype" HLA of H1N1 isolates. Numbers in ( ) are CTL epitopes restricted by the HLA supertype of H1N1 isolates also conserved in GD06. Conservation (%) represents the percentage of conserved CTL epitopes from the total number of CTL epitopes in GD06. KEVLVLWGI ** AELPFTIDK *** EEIRRVWRQ ** QEGRMNYYW *** AEIEDLIFL ** LENERTLDY ** YPKLSKSYI was not conservative in the HA of BJ/262/95 but conservative in the HAs of other three strains; FYKNLIWLV was only conservative in the HA of SI/3/06. NSDTVGWSW and WPDGAELPF were not conservative in the NA of SI/3/06 but conservative in the NAs of other three strains; AELPFTIDK was only conservative in the NA of BJ/262/95. *** showed 100% (9/9) conservation, ** 88.9% (8/9) conservation, * 77.8% (7/9) conservation. fluenza virus. In particular, the HLA class I epitope (CTL epitope) can activate CD8 + T-cells and is involved in both virus clearance and disease recovery (Boon et al., 2004; Kreijtz et al., 2007) . When compared to seasonal H1N1 vaccine strains from 1999 to 2010, the GD06 antigenic sites of HA and NA proteins showed 44.0-50.0% and 55.9-61.8% similarity, respectively. However, CTL epitopes of HA and NA proteins were highly conserved (60.5-65.8% and 69.6-82.6%, respectively) when compared to vaccine strains. The CTL epitopes of the NP protein were 76.7% conserved. Thus the cross-T-cell immunity, acquired due to the vaccination or exposure to seasonal H1N1 virus, may alleviate the disease progress of 2009 H1N1. The severity and mortality of 2009 H1N1 infections were similar to seasonal influenza (Uyeki, 2009; Cowling et al., 2010) . This epidemic feature was related to the low-pathogenic molecular characteristics of the 2009 H1N1 virus, and might also be associated with conserved T-cell epitope-induced cross-cell immunity after the infection with seasonal H1N1 viruses or vaccination.
Antibodies against the HA protein of the influenza virus can neutralize infectivity of the virus and, therefore, play an important role in the protection against viral infections (Skehel and Wiley, 2000 Manicassamy et al., 2010) . The high titer of cross-protective antibodies in people born before 1940, who are likely to have been previously infected with either 1918 H1N1 virus or an early progeny, might be responsible for their relatively low 2009 H1N1 infection rate.
Pandemic strain of influenza virus can evade the host immune response through the mutation of antigenic sites, enabling them to develop into seasonal epidemics. However, viral protein glycosylation, particularly the glycosylation near the RBD, can lead to an antigenic drift and escape from neutralizing antibodies against the virus by shielding antigenic sites. Thus, evasion of antibodies by glycosylation represents another mechanism for the development of seasonal flu from pandemic infections Cohen, 2010; Xu et al., 2010) . During the epidemic process of 2009 H1N1, some strains acquired mutations at antigenic sites; however, the variation of these sites was small, typically caused by the mutation of single amino acid at a single antigenic site. But it should be noted that several 2009 H1N1 strains had obvious variation at the glycosylation sites. Rome/623/09, Texas/45071344/09, and Texas/45103737/09, isolated after September 2009, gained new glycosylation site at the position 44 of the NA protein, the same as seasonal H1N1 viruses. It is of particular interest that Haishu/SWL110/10, Beijing/SE2649/09, Russia/178/09, Russia/180/09, and Salekhard/01/09, isolated after November 2009, gained a new glycosylation site at the position 179 of the HA protein near the RBD. Critically, the anti-serum against 2009 H1N1 California/04/09 cannot neutralize the infectivity of mutated strains with glycosylation at the position 179 of HA (Settembre et al., 2010; Wei et al., 2010) . This trend of resistance through glycosylation should be monitored closely to avoid a seasonal epidemic of 2009 H1N1. Studies have shown that antibody prepared by immunization of mice using HA proteins glycosylated near the RBD of 2009 H1N1 can bind to the HA protein with or without glycosylation (Wei et al., 2010) . Thus, in the future strategy of vaccine development, vaccination with glycosylated 2009 H1N1 virus may prevent the seasonal epidemic caused by mutated strains with glycosylation near the RBD.
